Condition: Secondary Hyperparathyroidism · Chronic Kidney Disease · Sponsor: Amgen
This is a phase 3 trial of etelcalcetide in pediatric participants with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) on hemodialysis.
This description comes directly from the study's public registry record.
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
| Childrens Hospital of Los Angeles | Los Angeles, California, United States | Recruiting |
| Childrens Hospital Colorado | Aurora, Colorado, United States | Terminated |
| Childrens Mercy Hospital | Kansas City, Missouri, United States | Recruiting |
| Mount Sinai Kidney Center - B1 Renal Treatment | New York, New York, United States | Completed |
| Cincinnati Childrens Hospital Medical Center | Cincinnati, Ohio, United States | Completed |
| Cleveland Clinic Foundation | Cleveland, Ohio, United States | Recruiting |
| The Childrens Hospital at Oklahoma University Medical Center | Oklahoma City, Oklahoma, United States | Completed |
| Childrens Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| Childrens Medical Center Dallas | Dallas, Texas, United States | Terminated |
| Primary Childrens Hospital Outpatient Services | Salt Lake City, Utah, United States | Recruiting |
| Fresenius Escobar | Belen de Escobar, Buenos Aires, Argentina | Terminated |
| Hospital Italiano | Cuidad Autonoma de Buenos Aires, Buenos Aires, Argentina | Recruiting |
+ 31 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03633708